Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth ...
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback